Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas

Journal of Chemotherapy

Volumn 10, Issue 5, 1998, Pages 385-393

  Comandone, A ^a,d   Leone, L ^b   Oliva, C ^a   Frustaci, S ^c   Monteleone, M ^b   Colussi, A M ^c   Dal Canton, O ^a   Bergnolo, P ^a   Boglione, A ^a   Bumma, C ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d GRADENIGO HOSPITAL   (Italy)

Author keywords

Bone sarcoma; Ifosfamide; Pharmacokinetics; Sarcoma; Soft tissue sarcoma

Indexed keywords

DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; MESNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; OSTEOSARCOMA; SOFT TISSUE SARCOMA;

EID: 15444343870     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.5.385     Document Type: Article

References (33)

1. Antman KH. Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol 1992; 6, Suppl 12: 13-22.
2. Gad El Mowha. Ifosfamide in advanced pancreatic cancer: a five year experience. Cancer Chemother Pharmacol 1986; 18, Suppl 2: S55-S56.
3. Ardizzoni A, Fusco V, Gulisano M, Pronzato P, Baracco F. Etoposide, ifosfamide and cisplatin in the treatment of advanced non small cell lung cancer. Cancer Treat Rep 1987; 71: 1311-1312.
4. Cabanillas F. Ifosfamide combinations in lymphoma. Semin Oncol 1990; 2, Suppl 4: 58-62.
5. Lare PC, Garcia-Puche JL, Pedraza V. Cisplatin-ifosfamide in neoadjuvant chemotherapy in stage IIIB cervical uterine squamous cell carcinoma. Cancer Chemother Pharmacol 1990; 26 (S): 36-38.
6. Lund B, Hansen M, Handen OP, Hansen HH. Combined high dose carboplatin and cisplatin and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1990; 8: 1226-1230.
7. Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E. The role of ifosfamide plus cisplatin based chemotherapy as salvage therapy for patients with refractory germ cell tumours. Cancer 1990; 66: 2476-2481.
8. Wolf M, Havemann K, Holle R, Gropp C, Drings P. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small cell lung cancer: a multicenter German randomized trial. J Clin Oncol 1987; 5: 1880-1889.
9. Millward MS, Harris AL, Contwell BMJ. Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer 1990; 65: 2421-2425.†
10. Sarosy G. Ifosfamide - pharmacologic overview. Semin Oncol 1989; 1, Suppl 3: 2-8.
11. Boddy AV, Cole M, Pearson DDJ, Idle JR. The kinetic of the autoinduction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol† 1995; 36: 53-60.
12. Shaw IC, Graham MI. Mesna: a short review. Cancer Treat Rev 1987; 14: 67-86.
13. Casali P, Pastorino U, Azzarelli A, et al. Prospectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 1993; 31, Suppl. 2: 228-232.
14. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard and high-dose schedules. Semin Oncol 1990; 2, Suppl 4: 68-73.
15. Toma S, Palumbo R, Comandone A, et al. Ambulatory 4-days continuous infusion schedule of high dose ifosfamide with mesna uroprotection and granulocyte colony stimulating factor in advanced solid tumours: a phase I study. Ann Oncol 1995; 6: 193-196.
16. Bertulli M, Casali P, Mastore M, Santoro A, Bonadonna G. High dose ifosfamide as a second line chemotherapy for advanced adult soft tissue sarcomas patients. Ann Oncol 1994; 5, Suppl 8: 878.
17. Brain E, La Cosne A, Le Chevalier T. High dose Ifosfamide can circumvent resistance to standard dose ifosfamide in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1993; 12, 470: 1641.
18. Patel S, Benjamin RS. Standard and high dose chemotherapy for advanced soft tissue sarcomas. Ann Oncol 1992; 3, Suppl. 2: 81-83.
19. Buonadonna A, Romanini A, Comandone A, Della Palma M, Verusio C, Frustaci S. Increasing continuous infusion ifosfamide and bolus epirubicin in soft tissue sarcoma patients. Proc Am Soc Clin Oncol 1996; 522: 1683.
20. Brade WP, Herdrick K, Varini M. Ifosfamide pharmacology, safety and therapeutical potential. Cancer Treat Rev 1985; 12: 1-47.
21. Haney D, Lewis JJ, Bailey CC. Acute ifosfamide induced tubular toxicities. Correspondence. Lancet 1989; 2: 103-104.
22. Brock N. Oxazaphosphorine cytostatics: past-present-future. Cancer Res 1989; 49: 1-7.
23. Smeitink J, Verreussel M, Schroder C, Lippens R. Nephrotoxicity associated with ifosfamide. Eur J Ped 1988; 148: 164-166.
24. van Dyk JJ, Falksan HC, van der Merwe AM, Falkson G. Unexpected toxicity in patients treated with ifosfamide. Cancer Res 1972; 32: 921-924.
25. Kurowski V, Wagner T. Comparative phamacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993; 33: 36-42.
26. Lewis LD, Fitzgerald DL, Harper PG, Rogers HS. Fractionated ifosfamide therapy produces a time dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990; 30: 725-732.
27. Brade WP, Herdrich K, Araujo CE. Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 1991; 117, Suppl. 4: 164-186.
28. Boddy AV, Jule SM, Wyllie L, Price R, Pearson ADI, Idle JR. Pharmacokinetics and metabolism in children of ifosfamide administered as a continuous infusion. Cancer Res 1993; 53: 3758-3764.
29. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995; 31A, 5: 785-790
30. Rustum AM, Hofmma NE. Determination of cyclophosfamide in whole blood and plasma by reversed-phase high performance liquid chromatography. J Chromatogr 1987; 422: 125-134.
31. Leone L, Comandone A, Oliva C, et al. Stability of ifosfamide in solution for multiday infusion by external pump. Anticancer Drugs 1995; 6: 604-607.
32. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301-355.
33. Wagner T, Ehninger G. Self induction of cyclophosphamide and ifosfamide metabolism by repeated high dose treatment. In Brade et als (eds). Ifosfamide in tumours therapy. Contribution to Oncology Karger, Basel, 1987: vol. 26, 69-75.